Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Sep;3(9):731-4.
doi: 10.1002/ccr3.329. Epub 2015 Jul 23.

Cardiac rhythm abnormalities during intravenous immunoglobulin G(IVIG) infusion in two newborn infants: coincidence or association?

Sinan Tufekci  1 , Asuman Coban  1 , Meltem Bor  1 , Beril Yasa  1 , Kemal Nisli  2 , Zeynep Ince  1
Affiliations
Case Reports

Cardiac rhythm abnormalities during intravenous immunoglobulin G(IVIG) infusion in two newborn infants: coincidence or association?

Sinan Tufekci et al. Clin Case Rep. 2015 Sep.

Abstract

We report the occurrence of supraventricular tachycardia during intravenous immunoglobulin (IVIG) infusion. Supraventricular tachycardia was observed in two newborn patients during IVIG infusion. Both of the babies responded to adenosine treatment. Cardiorespiratory monitoring during IVIG infusion can be recommended because of the possibility of this potentially lifethreatening adverse effect.

Keywords: Cardiac rhythm abnormalities; intravenous immunoglobulin G; newborn.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Supraventricular tachycardia during IVIG treatment and normal heart rhythm after the administration of adenosine.
Figure 2
Figure 2
Supraventricular tachycardia during IVIG treatment and normal heart rhythm after the administration of adenosine.
See this image and copyright information in PMC

References

    1. Savaşan S, Tuzcu V, Warrier I. Karpawich P. Cardiac rhythm abnormalities during intravenous immunoglobulin G infusion for treatment of thrombocytopenia. J. Pediatr. Hematol. Oncol. 1997;19:254–257. - PubMed
    1. Alarcon PAD, Werner EJ. Cristensen RD. Chapter 6, Hemolytic disease of the fetus and newborn. In: Ross ME, Waldron PE, Cashore WJ, editors; Neonatal hematology. 2nd ed. Edinburgh: Cambridge Univ. Press; 2013. pp. 65–90. , ed., and.
    1. Ohls RK, Maheshwari A. Polin RA. Chapter 6, Diagnosis and treatment of immune-mediated and non-immune-mediated hemolytic disease of the newborn. In: Patel S, editor; Hematology, immunology and infectious disease. 2nd ed. Philadelphia: Elsevier Saunders; 2012. pp. 75–88. , ed., and.
    1. Pierce LR. Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev. 2003;17:241–251. - PubMed
    1. Orange JS, Hossny EM, Weiler CR, M Ballow, Berger M. Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006;117:S525–S553. - PubMed

Publication types

LinkOut - more resources